Compounds 1-14 were synthesized in a search for high-affinity CRF 1 receptor ligands that could be radiolabeled with 11 C or 18 F for use as positron emission tomography (PET) radiotracers. Derivatives of 2 were developed which contained amide N-fluoroalkyl substituents. Compounds [ 18 F]24 and [ 18 F]25 were found to have appropriate lipophilicities of logP 7.4 = 2.2 but microPET imaging with [ 18 F]25 demonstrated limited brain uptake.
The neuropeptide corticotropin-releasing factor (CRF) 1, 3 coordinates the neuroendocrine response to stress through the hypothalamic-pituitary-adrenal axis by acting on the CRF Type-1 (CRF 1 ) receptor. 4 Dysregulation of brain CRF signaling has been proposed to be involved in stress, anxiety, depression, and addiction; and brain regional alterations in CRF 1 density have been detected in depressed patients and victims of suicide. [5] [6] [7] [8] This evidence has resulted in a more than 20-year search for small molecule, brain bioavailable CRF 1 antagonists that could be used as therapeutics for treating CRF 1 -related disorders. [9] [10] [11] Therapeutic medication development can be uniquely aided by the availability of validated positron emission tomography (PET) and single-photon emission computed tomography (SPECT) radiotracers that can be used to both support target occupancy measurements of candidate therapeutics and to explore mechanisms of pathophysiology and treatment response by measurement of receptor density and expression levels. [12] [13] [14] [15] Numerous attempts to develop a viable brain CRF 1 receptor PET radiotracer have been reported over the years but no candidates to date have been successful due to problems such as high lipophilicity and inability to cross the blood-brain barrier (BBB), rapid metabolism, or insufficient specific receptor binding. [16] [17] [18] [19] As part of an effort to develop a viable brain CRF 1 receptor PET tracer we have been exploring various structural motifs 20 and report here our results with compounds 1-15 (Scheme 1), and derivatives thereof, which are based on a previous report that compounds 2, 6, and 9 displayed high binding affinity (IC 50 = 0.70, 0.49, and 0.92 nM, respectively) at the rat brain CRF 1 receptor. 21 We anticipated that the reported high binding affinity of 2, 6, and 9 would enable radiotracer derivatives of this structural class to achieve specific binding at CRF 1 and that the presence of the carbonyl group would enhance water solubility, thereby reducing logP and increasing BBB passage. [22] [23] [24] [25] Furthermore, the synthetic route for this class of compounds 21 (Scheme S1, Supplementary Material) allows the aromatic core and the N,N-dialkyl group to be held constant while the 2,4-substituted pendant aryl ring is varied to produce a library of high-affinity candidates that are amenable to radiolabeling with 11 C or 18 F.
The binding affinities of compounds 1-14 at the CRF 1 and CRF 2 receptors were determined by in vitro competition binding assays at 23 °C using HEK293T cells transfected with the human CRF 1 or CRF 2 receptor (Table 1 ). Compounds 1-14 all bound to the CRF 1 receptor with high affinity (K i = ~1.3-5.4 nM). Thus, although these compounds have various combinations of substituents on the pendant aryl ring, they all have binding affinities within a narrow range that differs by ~4 nM. The difference in affinities of 2, 6, and 9 between our results and the previously reported results 21 is presumably due to the difference between human and rat CRF 1 receptors as well as the fact that we are reporting K i values and the previous work reported IC 50 values. Sauvagine and R121919 26 were used as positive controls in our assays: R121919 was found to have an affinity of K i = 2.6 ± 0.4 nM for the CRF 1 receptor which is comparable to the previously reported values of K i = 3.5 nM 26 and K i = 3.0 ± 0.16 nM; 27 and sauvagine was found to have an affinity of K i = 0.8 ± 0.1 nM which is in agreement with the previously reported value of K i = 0.8-1 nM. 28 The competing radioligand for these studies, [ 125 I]-Tyr 0 -sauvagine, has a reported affinity of 0.2-0.4 nM for the CRF 1 receptor. 28 Compounds 1-3, 6, and 8-12 did not display binding affinity at the CRF 2 receptor (they were unable to significantly displace [ 125 I]antisauvagine-30), 29 thus demonstrating selectivity for the CRF 1 receptor and so further screening of compounds 4, 5, 7, 13, and 14 at the CRF 2 receptor was not performed.
Compound 1 was found to have the highest binding affinity for the CRF 1 receptor followed by compounds 2-5, but these compounds do not have a position available for radiolabeling with 11 C or 18 F. Thus, we shifted our focus to derivatives that could potentially be radiolabeled on the amide nitrogen atom. Compound 16 (Scheme 2) was prepared by amide N-methylation of 1 with CH 3 I. This resulted in only a small decrease in CRF 1 binding affinity ( 
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Author Manuscript N-fluoroalkyl target compounds. The shorter N,N-dialkyl chains of 17-19 were expected to compensate for the increased lipophilicity that would result from adding alkyl groups to the amide nitrogen atom, while 20 was included to evaluate the effect on binding affinity of rearranging the methylene groups of the N,N-dialkyl substituent of 2 into a symmetrical substitution pattern. Furthermore, derivatives of 2 were used, rather than 1, because 2bromo-4-iso-propylaniline can be reacted neat without the need for solvent or NaH which simplified the synthetic procedure. Compounds 21-25 (Scheme 3) were synthesized (Scheme S2, Supplementary Material) by N-alkylation of the amide nitrogen atom.
Replacing the N-butyl-N-ethyl substituent of 2 with N,N-dimethyl to give 17 resulted in a ~75-fold loss of binding affinity at CRF 1 ( Table 2 ) compared to 2 ( Table 1 ) due to the inability to fill the requisite lipophilic binding pocket on the receptor. 21 (Table 3) were measured by the octanol/aqueous buffer shake-flask method 33, 34 and were both found to be logP 7.4 = 2.2 which is in the range for passive diffusion across the BBB. 22, 23, 25 MicroPET imaging was performed in an anesthetized male cynomolgus monkey using a Siemens MicroPET Focus 220 as previously described. 20 The whole-brain time-activity curves (TACs) for [ 18 F]25 (Figure 1) show that the radiotracer did not significantly enter the brain (SUV = <1) even though the logP 7.4 value of [ 18 F]25 (Table 3 ) indicates that it should be able to diffuse across the BBB. 22, 23, 25 The binding affinity of 25 (Table 2) may not be as strong as would be desired for a CRF 1 PET tracer, but this would not affect entry of the radiotracer into the brain, only retention of the radiotracer once in the brain. Thus, it would appear that the radiotracer was metabolized in the blood.
In summary, compounds 1-14 were found to have high binding affinities at the CRF 1 receptor with a range of K i = ~1.3-5.4 nM, but the highest affinity compounds, 1-5, do not have positions available for radiolabeling with 11 C or 18 F (although 76 Br derivatives are a possibility). Using shorter N,N-dialkyl chains allows for amide N-alkylation but these changes reduce the binding affinities at the CRF 1 receptor. 
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